RECRUITING

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Attention-Deficit/Hyperactivity Disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in childhood. Children with ADHD struggle in school due to problems with attention and high levels of impulsivity and hyperactivity. They are at substantially increased risk for long-term difficulties into adulthood, including academic underachievement, substance abuse, and criminal behavior. The diagnosis of ADHD, which is based on subjective ratings by parents and teachers, likely results from multiple different, overlapping differences in circuits of the brain responsible for attention and impulse control. However, we do not have any scientific or clinical tests that allow us to understand these circuits. In an effort to improve ADHD outcomes, we have used a technology called Transcranial Magnetic Stimulation (TMS) to identify highly reliable measurements of brain function. We have identified two very promising measures that are abnormal in children with ADHD and, importantly, also predict the severity of ADHD behaviors. The goal of this project is to determine if these two TMS measurements could be used to help better guide ADHD treatment. To do this, we will perform three investigations in 8 to 12 year old children to determine: 1) test-retest reliability; 2) pharmacologic responsiveness; and 3) correlations with two domains of function relevant to ADHD: "Cognitive Control" and "Emotional Valence." Through these investigations, we aim to determine whether these two TMS brain measures are reliable and meaningful enough to be used to help improve precision of individually-targeted and effective ADHD treatments.

Official Title

Anomalous Motor System Physiology in Attention Deficit Hyperactivity Disorder: Biomarker Validation and Modeling Domains of Function

Quick Facts

Study Start:2021-06-01
Study Completion:2026-04-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04421248

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:8 Years to 12 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * Either gender, any race, ethnicity or socioeconomic status
  2. * Currently between 8 years 0 months and 12 years, 11 months, 30 days
  3. * Willing to answer questions about ADHD and related diagnoses
  4. * For children with ADHD prescribed stimulant medications, willing to suspend taking medications as specified in the study procedures
  5. * For children with ADHD, willing to participate in the single dose, randomized crossover study to probe acute effects of methylphenidate on biomarkers
  6. * Right hand dominant (predominately right-handed)
  7. * Able to participate in and sign an informed consent
  8. * ADHD inclusion: The diagnosis of ADHD will be based on Diagnostic and Statistical Manual version 5 (DSM-5) criteria using standard rating scales and a structured diagnostic interview. Oppositional Defiant Disorder is permitted; Conduct disorder is excluded.
  9. * Typically Developing (healthy control) inclusion: Free of ADHD or other developmental or psychiatric disorders based on DSM-5 criteria using standard rating scales and a structured diagnostic interview.
  1. * Known diagnosis of mental retardation, cerebral palsy, Autism Spectrum Disorder, traumatic brain injury, brain tumor, epilepsy, or other serious neurological disorder.
  2. * Major Depression, Bipolar Disorder, Conduct Disorder, Adjustment Disorder, other Anxiety Disorders, or other developmental psychiatric diagnoses.
  3. * For females, onset of menses, pregnancy.
  4. * Current use of antidepressants, non-stimulant ADHD medications, dopamine blocking agents, mood stabilizers.
  5. * Implanted brain stimulator, vagal nerve stimulator, ventriculo-peritoneal shunt, cardiac pacemaker, or implanted medication port.
  6. * Diagnosis of a speech/language disorder or a Reading Disability (RD).

Contacts and Locations

Study Contact

Donald L Gilbert, MD
CONTACT
800-344-2462
donald.gilbert@cchmc.org
Steve W Wu, MD
CONTACT
800-344-2462
steve.wu@cchmc.org

Principal Investigator

Donald L Gilbert, MD
PRINCIPAL_INVESTIGATOR
Children's Hospital Medical Center, Cincinnati
Stewart H Mostofsky, MD
PRINCIPAL_INVESTIGATOR
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Study Locations (Sites)

Kennedy Krieger Institute
Baltimore, Maryland, 21205
United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
United States

Collaborators and Investigators

Sponsor: Donald Gilbert, MD, MS, FAAN, FAAP

  • Donald L Gilbert, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital Medical Center, Cincinnati
  • Stewart H Mostofsky, MD, PRINCIPAL_INVESTIGATOR, Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-06-01
Study Completion Date2026-04-01

Study Record Updates

Study Start Date2021-06-01
Study Completion Date2026-04-01

Terms related to this study

Additional Relevant MeSH Terms

  • Attention Deficit Hyperactivity Disorder Combined